Eli Lilly and Company reported third quarter results and ... In the following article, I will look at Eli Lilly once again and try to answer what perspective is correct. Should we actually be ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

Bad optics, that’s all I’ll say. For long-term success, Eli Lilly—or any company, for that matter—needs to perform in the short term while transforming for the long haul. That means ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. The reason for the disappointing sales, according to the ...

Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue ... peers fare on metrics that matter. You will find other ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

Senators led by Sen. Dick Durbin (D-Ill.) on Monday demanded answers from Pfizer and Eli Lilly about their relationship with the telehealth prescribers they point patients to from their websites ...

But earnings in the new range would still wind up being more than twice what the company registered for 2023. Shares of Indianapolis-based Eli Lilly and Co. were down 6%, or $57.02, to $846.56 in ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. During an earnings call Wednesday, Eli Lilly instead blamed ...